Research programme: guanylate cyclase C agonists - Synergy

Drug Profile

Research programme: guanylate cyclase C agonists - Synergy

Alternative Names: GC-C receptor agonists - Synergy

Latest Information Update: 25 Oct 2012

Price : $50

At a glance

  • Originator Synergy Pharmaceuticals Inc
  • Class Peptide hormones; Peptides
  • Mechanism of Action Guanylate cyclase C agonists; Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypercholesterolaemia
  • No development reported Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 25 Oct 2012 No development reported - Preclinical for Inflammatory bowel disease in USA (PO)
  • 25 Oct 2012 No development reported - Preclinical for Ulcerative colitis in USA (PO)
  • 30 Mar 2012 Synergy Pharmaceuticals may consider licensing or partnering guanylate cyclase stimulants developed under this research programme - http://www.synergypharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top